CSII has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CSII has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardiovascular Systems's Enterprise Value is $733.2 Mil. Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-36.1 Mil. Therefore, Cardiovascular Systems's EV-to-EBIT for today is -20.31.
The historical rank and industry rank for Cardiovascular Systems's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of Cardiovascular Systems was 1690.65. The lowest was -1295.36. And the median was -21.32.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cardiovascular Systems's Enterprise Value for the quarter that ended in Dec. 2022 was $460.8 Mil. Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-36.1 Mil. Cardiovascular Systems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -7.83%.
The historical data trend for Cardiovascular Systems's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiovascular Systems Annual Data | |||||||||||||||||||||
Trend | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | 276.08 | 863.52 | -41.56 | -133.85 | -12.86 |
Cardiovascular Systems Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
EV-to-EBIT | Get a 7-Day Free Trial | -22.59 | -25.24 | -12.86 | -12.33 | -12.76 |
For the Medical Devices subindustry, Cardiovascular Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cardiovascular Systems's EV-to-EBIT falls into.
Cardiovascular Systems's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 733.190 | / | -36.101 | |
= | -20.31 |
Cardiovascular Systems's current Enterprise Value is $733.2 Mil.
Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiovascular Systems (NAS:CSII) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Cardiovascular Systems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2022 ) |
= | -36.101 | / | 460.80592 | |
= | -7.83 % |
Cardiovascular Systems's Enterprise Value for the quarter that ended in Dec. 2022 was $460.8 Mil.
Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cardiovascular Systems's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey S. Points | officer: Chief Financial Officer | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Scott R Ward | director | RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077 |
Erik Paulsen | director | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Rhonda J. Robb | officer: Chief Operating Officer | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Martha Goldberg Aronson | director | 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350 |
Sachin H. Jain | director | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Alexander Rosenstein | officer: General Counsel & Corp. Secy | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Sandra Sedo | officer: Chief Compliance Officer | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Kelvin K. Womack | director | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Stephen J. Rempe | officer: Chief Human Resources Officer | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
John M. Hastings | officer: VP Manufacturing & Operations | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Stephen Stenbeck | director | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Ryan Egeland | officer: VP of Medical Affairs | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
David Whitescarver | officer: VP of Corp. Dev. & IP | C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112 |
Laura Gillund | officer: Chief Talent Officer |
From GuruFocus
By Business Wire Business Wire • 03-04-2022
By Business Wire Business Wire • 10-17-2022
By Business Wire Business Wire • 02-13-2023
By sperokesalga sperokesalga • 02-19-2023
By Business Wire Business Wire • 01-19-2023
By Business Wire Business Wire • 02-09-2023
By PRNewswire PRNewswire • 02-16-2023
By Business Wire Business Wire • 03-09-2022
By PRNewswire PRNewswire • 02-28-2023
By Business Wire Business Wire • 03-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.